We next verified in the TCGA that there was no statistically difference; however, patients in the BRAF mutation group showed a trend toward a higher risk than those in the non-mutation group ( Supplementary Fig. 4 I).
← all excerpts
Anoikis-related signature identifies tumor microenvironment landscape and predicts prognosis and drug sensitivity in colorectal cancer.
1
—
—